Responder rates at Week 52 in QUEST (secondary endpoint)1,2,a,b

Improved asthma control in patients, as measured by ACQ-5
Baseline Blood
EOS ≥300 cells/μL - QUEST
75%
of patients improved

with DUPIXENT 200 mg + SOC
vs 67% with placebo + SOC
(OR: 1.46 [95% CI: 0.90, 2.35])

71%
of patients improved

with DUPIXENT 300 mg + SOC vs 64% with placebo + SOC (OR: 1.39 [95% CI: 0.88, 2.19])

ACQ-5: Asthma Control Questionnaire, 5-item version, a patient-reported measure of asthma control. Higher scores indicate less asthma control; a global score is calculated ranging from 0 to 6. The minimum clinically important difference is 0.5.1

 

Improved asthma in patients’ quality of life, as measured by AQLQ(S)
Baseline Blood
EOS ≥300 cells/μL - QUEST
71%
of patients improved

with DUPIXENT 200 mg + SOC
vs 55% with placebo + SOC
(OR: 2.02 [95% CI: 1.24, 3.32])

65%
of patients improved

with DUPIXENT 300 mg + SOC
vs 55% with placebo + SOC
(OR: 1.79 [95% CI: 1.13, 2.85])

AQLQ(S): Asthma Quality of Life Questionnaire, Standardized Version, a patient-reported measure of asthma-related quality of life. Higher scores indicate better quality of life; a global score is calculated ranging from 1 to 7. The minimum clinically important difference is 0.5.1

aResponder rates were defined as an improvement in score of 0.5 or more (scale ranged from 0 to 6 for ACQ-5 and 1 to 7 for AQLQ[S]).1

bACQ-5 and AQLQ(S) were assessed as secondary endpoints, but were ordered after the point at which the hierarchical break occurred. Results are descriptive.2

QoL, quality of life.

EXPLORE THE SAFETY DATA AND STUDY DESIGNS

VIEW SAFETY DATA SEETHE FULL STUDY DESIGNS

Dosage and Administration
See the dosage and administration options for patients on DUPIXENT.
Explore ADMINISTRATION Options